High-risk, high-grade (T1G3) bladder cancer: Models versus reality

Cancer

Volumn 115, Issue 23, 2009, Pages 5366-5367

  Herr, Harry W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

BLADDER CANCER; CANCER CONTROL; CANCER GRADING; CANCER RISK; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; CYSTECTOMY; EDITORIAL; PRIORITY JOURNAL; QUALITY OF LIFE;

AGED; AGED, 80 AND OVER; BCG VACCINE; CYSTECTOMY; HUMANS; MIDDLE AGED; RISK; URINARY BLADDER NEOPLASMS;

EID: 72249117973     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24553     Document Type: Editorial

References (5)

1. Kulkarni GS, Alibhai SMH, Finelli A, et al. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer. 2009;115:5450-5459.
2. Kulkarni GS, Finelli A, Fleshner N, et al. Optimal management of high-risk T1G3 bladder cancer: a decision analysis [serial online]. PLoS Med.2007;4:e284.
3. Jemal A, Ward E, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71-96.
4. Froehner M, Studer UE, Herr HW, et al. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol.2009 May 18. [Epub ahead of print].
5. Siegrist TC, Cronin AM, Donat SM. Radical cystectomy in octogenarians: does morbidity outweigh the potential benefits? J Urol. In press.